$785 Million for Tropical Diseases

A public-private partnership including 13 pharmaceutical companies pledge more than $785 million to fight neglected tropical diseases.

Written byHannah Waters
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Bill Gates at the World Economic Forum Annual Meeting on Jan 26, 2012FLICKR, WORLD ECONOMIC FORUM

Some are calling it an unprecedented collaboration: 13 pharmaceutical companies, the Bill and Melinda Gates Foundation, the World Health Organization, The World Bank, and the US, UK, and UAE governments, and other groups have come together to fight neglected tropical diseases. Neglected tropical diseases tend to afflict the world’s poorest people, and thus companies have fewer incentives to invest in medicines and cures.

The partnership, announced yesterday (January 30) at the Royal College of Physicians in London, will focus on ten tropical diseases, including Chagas disease, guinea worm, and sleeping sickness. Drugmakers agreed to continue or expand drug donation programs through 2020 while sharing protocols and materials with one another to hasten new drug development. In total, the groups donated more than $785 million for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies